# Inferred resolution through herd immmunity of first COVID-19 wave in Manaus, Brazilian Amazon

Thomas A. A. Prowse<sup>1,¶</sup>, T. Purcell<sup>2,¶</sup>, Djane C. Baía-da-Silva<sup>3</sup>, V. Sampaio<sup>4</sup>, Wuelton M. Monteiro<sup>5</sup>, James Wood<sup>6</sup>, I. Mueller<sup>7,8</sup>, Jodie McVernon<sup>9,10,11</sup>, Marcus V. G. Lacerda<sup>12,#</sup>, Joshua V. Ross<sup>1,#</sup>

<sup>1</sup>School of Mathematical Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia

<sup>2</sup>Victorian Infectious Diseases Reference Laboratory Epidemiology Unit at The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Victoria 3000, Australia

<sup>3</sup>Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil

<sup>4</sup>Fundação de Vigilância em Saúde; Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil

<sup>5</sup>Universidade do Estado do Amazonas; Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil

<sup>6</sup>School of Population Health, UNSW Sydney, Australia

<sup>7</sup>Population Health and Immunity Division, Walter + Eliza Hall Institute, Parkville, Victoria, Australia

<sup>8</sup>Department of Medical Biology, FMDHS, University of Melbourne, Parkville; Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France

<sup>9</sup>Victorian Infectious Diseases Reference Laboratory Epidemiology Unit at The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, Victoria 3000, Australia

<sup>10</sup>Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne

<sup>11</sup>Infection and Immunity Theme, Murdoch Childrens Research Institute, Parkville.

<sup>12</sup>Instituto Leônidas & Maria Deane, Fiocruz; Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil

#Joshua V. Ross, School of Mathematical Sciences, The University of Adelaide, Adelaide, South Australia 5005, Australia

¶ equal first authors

# equal last authors NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

1

2

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Background

3 As in many other settings, peak excess mortality preceded the officially reported 'first wave'

peak of the COVID-19 epidemic in Manaus, Brazil, reflecting delayed case recognition and

limited initial access to diagnostic testing.

**Methods and Findings** 

To avoid early information bias, we used detailed age and gender stratified death certificate

and hospitalisation data to evaluate the epidemic's trajectory and infer the cause of its decline

using a stochastic model. Our results are consistent with heterogenous transmission reducing

from mid-April 2020 due to the development of herd immunity. Relative to a baseline model

that assumed homogenous mixing across Manaus, a model that permitted a self-isolated

population fraction reduced the population-wide attack rate required to drop the effective

reproduction number below one from 62 % to 47 %, and reduced the final attack rate from 86%

to 65%. In the latter scenario, a substantial proportion of vulnerable, older individuals remained

susceptible to infection.

**Conclusions** 

Our models indicate that the development of herd immunity amongst the mixing proportion of

the Manaus population had effectively halted the COVID-19 epidemic by late July 2020. Given

uncertainties regarding the distancing behaviours of population subgroups with different social

and economic characteristics, and the duration of sterilising or transmission-modifying

immunity in exposed individuals, we conclude that the potential for epidemic outbreaks

- remains, but that future waves of infection are likely to be much less pronounced than that 22
- 23 already experienced.

## Introduction

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

Globally, marked differences have been observed in morbidity and mortality due to SARS-CoV-2 infection. This variability mostly reflects the extent and timeliness of spontaneous and imposed changes in social mixing and the sensitivity of surveillance systems to detect cases and deaths [1]. Many countries that successfully constrained the initial epidemic through distancing measures are now experiencing second waves in still-susceptible populations [2]. Estimates of  $R_0$  for SARS-CoV-2 in the range 2 to 6 [3, 4] suggest that population immunity of approximately 50-80% is required to achieve herd protection. However, heterogeneous behaviour, infectivity and immunity within subpopulations could plausibly decrease this threshold to 10-20% [5]. Controversy remains regarding the extent of population exposure required to achieve such constraint [6]. Comparison of population attack rates to inform this question is made challenging by imperfect case ascertainment, compounded by limited diagnostics and overwhelmed health systems, particularly in high incidence settings. Assessment of epidemic activity therefore requires the use of less biased metrics than confirmed case reports. Excess mortality is an objective measure which, with cause-of-death certification, can be used as an indicator of direct and indirect COVID-19 associated mortality [7]. With hospitalisations data, it can inform retrospective estimation of cumulative cases and deaths [8]. Brazil experienced a severe first wave of COVID-19 disease, with mass mortality reported in many states, mainly in the north where seasonality of respiratory infections contributed to higher vulnerability. A socialized health system provided free and global access to tertiary care hospitals, but inequalities might explain different mortality rates in the population [9]. In Manaus, the highly urbanised capital of Amazonas state, the first case of COVID-19 was

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

reported on 13 March 2020 [10]. By 11 August 2020, 37,597 cases and 2,051 deaths were reported [11]. However, burial and death records indicate far higher mortality than official reports, suggesting late recognition of importation and underreporting. Previous studies have assumed that the first wave in Manaus was significantly mitigated by non-pharmaceutical interventions (NPIs) [12]. While these restrictions may have partly constrained early transmission, local reports indicate that implementation was highly variable [13]. Moreover, a possible role for immunity is suggested by the observation of declining cases and deaths over a period in which restrictions were officially eased. We use death certificate and hospitalisation records to parameterise an epidemiological model of the COVID-19 epidemic in Manaus. The model allows inference of age- and genderstratified infection-fatality ratios to explore evidence for development of herd immunity as a driver of local epidemic resolution, with implications for the ongoing risk posed by SARS-CoV-2 to this population. **Methods Excess mortality and reported causes** Death certificate data from January 2015 to July 2020 were sourced from the Brazilian Ministry of Health Mortality Information System (SIM). Information on age, gender, and cause and date-of-death was recorded. Cause of death was reported using the World Health Organization's (WHO) International Classification of Diseases 10<sup>th</sup> revision (ICD-10). The 2010 population census and the 2019 municipal population estimates were accessed from the Brazilian Institute of Geography and Statistics (IBGE). This project was approved by the

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

Fundação de Medicina Tropical Dr Heitor Vieira Dourado Ethics Review Board (Approval 4.033.218). Background mortality was calculated by averaging the number of deaths observed per week, commencing on January 1 each year, for the previous 5 years (2015-2019). Background mortality was further stratified by gender and into 5-year age bands, culminating at 75+. For each subgroup, we subtracted this five-year average from deaths observed for the period between March 19 and June 24 of 2020 to determine excess deaths. This period was selected as excess mortality was first observed in the week beginning on March 19 and the data returned to baseline background mortality in the week beginning on June 25. The age and gender structure reported in the 2010 population census was used to estimate the 2019 population size for each age and gender class. Population estimates were aggregated into 5-year age bands. The 5-year population estimates for 2019 were used to determine excess mortality, as a proportion of the population. The ICD-10 codes assigned to each death certificate were aggregated into 7 categories: diseases of the respiratory system (J00-J99), circulatory system (I00-I99), endocrine system (E00-E99), unattended (R98) and unknown cause of death (R99), coronavirus infection (B34.2) and all remaining codes were categorised as 'other'. All analyses were performed using R software. **Hospitalisation data** Hospitalisation data for patients admitted to all hospitals (private and public) in Manaus from January 2020 to July 2020 was accessed from the Influenza Surveillance Information System (SIVEP-Gripe). Data entry in this system is compulsory by law. A deidentified line list included patient demographics, comorbidities, clinical symptoms, investigations, clinical management and outcome data.

Daily admissions to both hospital and intensive care units (ICU) were aggregated each week in 2020 and stratified into 3 age bands (0-29, 30-64 and 65+). For each week, the proportion of hospital and ICU admissions within each age group was determined. Between April and July, the proportional distribution of hospital and ICU admissions across the three categories remained fairly stable, with no evidence of rationing of service access on the basis of age.

## **Epidemiological model**

We developed a stochastic, discrete-time, susceptible-infected-recovered epidemiological model for Manaus which we calibrated using daily time-series data from the death-certificate and hospitalisation records. The model assumed an initial population size equal to that of Manaus in 2019 (2,182,761), which was split into N=36 age/gender groups based on proportions reported in the 2010 census (i.e., 5-year age classes up to an age of 75 years, and then a pooled age class for all individuals aged 75 years and over). To allow inference on the background mortality rate in each age/gender group, the model was initiated on January 1, 2020, approximately two months prior to the introduction of COVID-19. The model was terminated after n=202 days on July 20, 2020, to ensure complete reporting of both death certificates and hospitalisations over the modelled period. The model detailed below was fitted within a Bayesian framework using JAGS (v. 4.3.0) software [14] and a mixture of informative and uninformative priors (for full details of the model code, including details of all prior distributions, see Supplementary Appendix S1).

**COVID-19 introduction and virus transmission**. We initialised the model by allowing importation of COVID-19 cases into Manaus over the week beginning March 5, 2020 (one week before the first reported case), and inferred an importation model such that the number of introduced cases into each group in each day of this first week arose from a Poisson process

with a common mean inferred from the data. To model community transmission, we inferred a reproduction number on day *t* that was modified by an index of human mobility

117 
$$R_t = e^{(\log(R_0) + aX_t)} \tag{1}$$

where  $R_0$  is the basic reproduction number,  $X_t$  is the mobility covariate and a is the inferred coefficient. We derived the time-series  $X_t$  by first averaging daily data for five separate indices of community mobility (available as the mobility change relative to baseline for retail/recreation, grocery/pharmacy, parks, transit stations and workplaces, accessed from <a href="https://www.google.com/covid19/mobility">www.google.com/covid19/mobility</a>), and then smoothed the series with a 7-day moving-average smoother. We then assumed the effective reproduction number  $R_{eff(i,j,t)}$  in group i due to mixing with group j on day t is

$$R_{eff_{(i,i,t)}} = R_t Q_i M_{i,j} S_{i,t}$$
 (2)

where  $Q_i$  is the susceptibility of group i to infection,  $M_{i,j}$  is the rate of mixing between the two groups, and  $S_{i,t}$  is the time-varying proportion of susceptible (previously uninfected) individuals remaining in the focal group. Based on previous studies [15, 16], we used prior means for the susceptibilities of 0-15, 15-60, and 60+ year old age classes of 0.5, 1.0, and 1.3, respectively.

Mixing between groups was governed by an age-structured mixing matrix reported previously for Brazil [17], which we corrected to be symmetrical (by averaging the upper and lower triangles), scaled to a mean of 1/N, and applied equally to both genders. The expected number of new cases in each group each day was then calculated as

135 
$$C_{i,t} = \sum_{j=1}^{N} R_{eff_{(i,j,t)}} \left( c_{j,1:(t-1)} \cdot g_{(t-1):1} \right)$$
 (3)

where  $c_{j,1:(t-1)}$  is the case-history vector for group j and  $g_{(t-1):1}$  is the portion of the generation interval distribution relevant to those cases. We used the same generation interval distribution as Mellan et al. [12] which concentrated >99% of an individual's infectivity within the first 3 weeks of infection (median generation interval=5 days).

To account for heterogeneity in transmission, we assumed the offspring distribution in group i due to mixing with infectious individuals from group j on day t was governed by a negative binomial distribution with mean equal to  $C_{i,t}$  and variance equal to  $C_{i,t}(1 + C_{i,t}/\emptyset_{i,t})$ , where

$$\phi_{i,t} = kC_{i,t}/R_t \tag{4}$$

and k is the overdispersion parameter, such that smaller values of k represent greater transmission heterogeneity (i.e., the more transmission is due to a small number of people, including by so-called "superspreaders"). Given no previous study has documented strong evidence of different susceptibility between genders, we first generated the expected number of new cases in each age class (regardless of gender), and then assumed gender-specific cases arose from a binomial distribution with probability equal to the proportion of the total susceptible individuals for that age class attributable to each gender.

**Background and COVID-induced mortality.** We developed a model for the expected number of deaths per day which was comprised of three components. First, we modelled the background (pre-COVID-19) death rate  $d_i$  estimated separately for each group. Second, available data on the time from symptom onset to death for confirmed COVID-19 cases (from the Manaus hospitalisation records) were used to infer a 4-parameter  $(y_0, u_{\min}, u_0, b)$  mortality distribution (m) as a function of the time x since symptom onset  $(x \in \{-5, ..., N-5\})$  of the form

157 
$$m_{x+a} = \frac{y_0 e^{u_{\min}(x+a) + ((u_0 - u_{\min})/b)(1 - e^{-b(x+a)})}}{\sum_{j=1}^{N} m_j}$$
 (5)

where a is the average time from infection to symptoms, which was fixed at 5 days [3, 18, 19]. Finally, we modelled the infection-fatality ratio in each group i ( $IFR_i$ ) as a log-linear function of age and gender, with prior distributions on this components' parameters based on a recent meta-analysis of COVID-19-induced mortality [20]. Together, these components yielded the following model for the expected number of deaths

163 
$$D_{i,t} = d_i + IFR_i \sum_{i=1}^{N} (c_{i,1:(t-1)} \cdot m_{(t-1):1})$$
 (6)

and the observed number of deaths each day was assumed to arise from a Poisson distribution with mean equal to  $D_{i,t}$ .

Hospitalisations due to COVID-19. Hospitalisations were modelled in a similar way to COVID-induced deaths, in that available data on the time from symptom onset to hospitalisation were used to infer a 4-parameter hospitalisation distribution (h) of the same functional form as that used for the mortality distribution above. We modelled the infection-hospitalisation ratio in each group i  $(IHR_i)$  as a logistic function of age and gender. Daily hospitalisations were assumed to arise from a Poisson distribution with mean equal to

172 
$$H_{i,t} = IHR_i \sum_{j=1}^{N} (c_{j,1:(t-1)} \cdot h_{(t-1):1})$$
 (7)

**Model scenarios.** Given no data were available on whether some portion of the Manaus population has been self-isolating since March 2020, we initially fitted a 'baseline' model to death-certificate and hospitalisation data which assumed homogeneous age-structured mixing across the entire Manaus population. We compared these model outcomes to those from a second model that permitted a self-quarantined proportion (*P*) of the population which could not be exposed to the SARS-CoV-2 virus. Communication with local experts including authors on this paper suggested that more wealthy residents of Manaus had been able to greatly reduce

social interactions during the first epidemic wave and avoid exposure to the virus. We reviewed detailed socio-demographic data on Manaus [21], but were not able to source quantitative estimates of the relevant population fraction. However, we considered that this would not exceed the upper 2 income quintiles (40%) of the population but was likely to be greater than the wealthiest 10%, and accordingly, chose a non-informative uniform (0.1,0.4) prior on this population fraction.

**Herd-immunity threshold.** To estimate the herd-immunity threshold for the baseline model scenario, we calculated the discrete-time next-generation matrix from the mixing matrix and posterior means for  $R_0$  and age-structured susceptibilities Q. We then calculated the deterministic reproduction number (R) as the dominant eigenvalue of this matrix, and estimated the herd-immunity threshold as 1 - 1/R. For each model, we also derived another estimate of this threshold that incorporated the inferred age/sex distribution of cases, by calculating the population-wide attack rate at which the expected number of offspring per case  $(R_{eff})$  multiplied by the normalised case-infectivity vector) fell below one.

#### Results

We calculated 3,457 excess deaths in Manaus, Brazil, between 19 March and 24 June 2020 (Supplementary Table 1) representing 0.16% of the city's population. Males 30 years and over experienced greater excess mortality than females; individuals aged 75 years or more accounted for 39% of the excess (Fig 1A). During this period, 7% of the 75+ male population in Manaus died (Fig 1B). COVID-19 deaths were first reported from 26 March and increased weekly thereafter in keeping with improved access to diagnostics and/or increasing prevalence (Fig 2), comprising 53% of the total excess. Other reported causes of death included respiratory diseases, unattended and unknown causes of mortality, cardiovascular, endocrine and cancer-

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

related mortality, the majority of which were compatible [22] with a clinical diagnosis of COVID-19 or are known comorbidities associated with severe outcomes (Fig 2). Stochastic transmission models captured the observed peak in excess deaths in late April, including age and gender variation (Fig 3, Figs S1 and S2). The models also captured synchronous peaks in hospitalisations (Fig 3, Figs S3 and S4), although model fit to these data was poorer, potentially reflecting delayed recognition of COVID-19 cases and/or capacity exceedance during the epidemic peak. Despite their different assumptions about the proportion of the Manaus population at risk, the two model scenarios yielded equivalent fits to the data (Fig 3A, B). The baseline model estimated heterogenous transmission (k=0.065 [0.047, 0.093], mean [95 % credible intervals]), a mean time-to-death of 13 days (Fig S5), and inferred a population-wide attack rate of 85.7 [84.6, 86.7]% by 20 July. Attack rates were lowest in younger age classes (Fig 3A,i), reflecting lower susceptibility assumed for people under 15 years. Infection fatality rate (IFR) estimates for the baseline model ranged from almost zero for both genders aged 30-35 years, to 3.0 [2.8, 3.3]% and 7.4 [6.8, 8.0]% for females and males over 75 years, respectively (Fig 4). At a population level, reduced mobility resulted in variable  $R_t$ , while the expected offspring per case fell below one after April 12 (Fig S6), when the estimated attack rate was 61.8 [61.1, 62.6]%. The traditional estimate of the herd-immunity threshold based on the discrete-time next-generation matrix calculated from this model was 71.8 %. Outcomes were similar for the second model which estimated Q = 24.5 [23.0, 25.1]% of the Manaus population was effectively removed from the susceptible pool. Relative to the baseline model, this second model estimated the expected offspring per case fell below one after April

11 when the attack rate was 46.8 [46.0, 47.7]%, and reduced the final attack rate to 65.0 [63.7, 226 65.6]%.

### **Discussion**

225

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

Early time-series modelling of the COVID-19 epidemic in Brazilian states up to 6 May 2020 used an unstructured model informed by state-level mobility indicators and reported deaths [12]. The model inferred population attack rates ranging from 0.13% to 10.6%, for Minas Gerais and Amazonas, respectively, and predicted ongoing epidemic growth throughout May. Other modelled  $R_0$  estimates based on reported COVID-19 cases from Amazonas state have similarly anticipated continued growth in cases through the month of June [13]. These models could neither explain nor accurately forecast observations of epidemic decline in Manaus. Our analysis of excess deaths and hospitalisations in Manaus identifies rapid epidemic growth from late March, peaking in late April, with a return to baseline mortality in early June. These age- and gender-stratified models inferred heterogeneous transmission consistent with previous studies of SARS-CoV-1 [23] and SARS-CoV-2 [24]. In the baseline model, the expected offspring per case fell below one at a population-wide attack rate of 61.8%. This model suggests the herd-immunity threshold was exceeded in Manaus, with resulting attack rates inferred to be 86% by July 20 2020. In contrast, the attack rate stabilised at 65 % for the second model which estimated the risk of infection applied to c. 75% of the population only. Both models suggest that, primarily due to herd protection, the expected number of offspring per cases fell below one in early April. Although both models estimated declining SARS-CoV-2 transmission over time due to herd immunity, their implications for the possibility of subsequent waves are qualitatively different. Although there are currently no data to support the assertion that some fraction of the Manaus

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

population self-isolated, we consider the second model is likely more realistic because: (1) the estimated infection-fatality ratios are higher than reported from high-income countries [25] which we anticipate to be plausible; and (2) a population attack rate of 65% is more consistent with recent estimates based on a Manaus blood bank serosurvey [26] which reported the largest increase in seropositivity over the month of April. We focus on Manaus as the epicentre of the COVID-19 epidemic in Amazonas, avoiding conflation of case numbers in this dense city of more than 2 million people with slower growing rural outbreaks across the state [6]. Given known information bias associated with limited early testing capacity, we used excess deaths and hospitalisations as the most objective indicators of epidemic activity presently available. Detailed cause-of-death data support the hypothesis that the majority of excess mortality over this time was COVID-19 related. An important caveat is that estimated attack rates accumulate all infections and are agnostic to the presence or degree of symptoms. Severity of the clinical course of COVID-19 is associated with magnitude and persistence of the host immune response [27]. In consequence, our estimates of 'exposure' cannot be directly related to predicted antibody seroprevalence at the end of the first wave [28]. It is reasonably anticipated that population immunity will wane over time, requiring robust memory responses [29] to prevent reinfection or modify the clinical course [30]. Our findings support emerging evidence that population heterogeneity of SARS-CoV-2 transmission, attributable to a range of biological and sociological factors, reduces the herd immunity threshold [24, 31, 32]. Reduction of superspreading events through constraints on mixing group sizes is concordant with genomic studies showing successive extinction of imported strains under the influence of social and mobility restrictions [33].

While future infection clusters and outbreaks remain possible in Manaus due to unexposed subgroups, population-level immunity will likely constrain widespread transmission unless immunity wanes. As in other settings, underlying vulnerability of older age groups may be further exacerbated over time by reduced health seeking behaviours of individuals with preexisting and new medical conditions [34]. Social measures should be informed by understanding of key enablers of superspreading and amplification, awareness of at-risk populations and tailored to context depending on population experience of the first wave. Excess mortality data are not sufficiently timely to support real-time decision making, but in areas with limited testing may be a more reliable indicator of past epidemic activity than confirmed cases. To accurately support response to and assess the impact of the COVID-19 and other public health emergencies, improved access to diagnostics, and strengthening of reporting systems are needed in low- and middle-income settings. Cross-sectional and longitudinal seroprevalence studies are essential to understand markers and maintenance of immunity to inform prediction of long-term epidemiologic trends and bridging to likely vaccine impacts [26, 35]. **REFERENCES** 

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

- 288 Dye C, Cheng R, Dagpunar J, Williams B. The scale and dynamics of COVID-19
- epidemics across Europe. 2020. 289
- 290 Klein A. Australia looks to be finally beating its second wave of coronavirus 2.
- 291 https://www.newscientist.com/article/2252690-australia-looks-to-be-finally-beating-its-
- 292 second-wave-of-coronavirus2020.
- 293 3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in
- 294 Wuhan, China, of Novel Coronavirus-Infected Pneumonia. 2020;382(13):1199-207. doi:
- 295 10.1056/NEJMoa2001316. PubMed PMID: 31995857.

- 296 4. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High
- 297 Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2.
- Emerging Infectious Disease journal. 2020;26(7):1470. doi: 10.3201/eid2607.200282. 298
- 299 5. Aguas R, Corder RM, King JG, Goncalves G, Ferreira MU, M. Gomes MG. Herd
- 300 immunity thresholds for SARS-CoV-2 estimated from unfolding epidemics.
- 301 2020;2020.07.23.20160762. doi: 10.1101/2020.07.23.20160762 %J medRxiv.
- 302 Ferrante L, Steinmetz WA, Almeida ACL, Leão J, Vassão RC, Tupinambás U, et al.
- 303 Brazil's policies condemn Amazonia to a second wave of COVID-19. Nature Medicine.
- 304 2020. doi: 10.1038/s41591-020-1026-x.
- 305 Felix-Cardoso J, Vasconcelos H, Rodrigues P, Cruz-Correia R. Excess mortality during
- 306 COVID-19 in five European countries and a critique of mortality analysis data.
- 307 2020;2020.04.28.20083147. doi: 10.1101/2020.04.28.20083147 %J medRxiv.
- 308 8. Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, et al.
- 309 Key questions for modelling COVID-19 exit strategies. Proc Biol Sci.
- 310 2020;287(1932):20201405. Epub 2020/08/13. doi: 10.1098/rspb.2020.1405. PubMed
- 311 PMID: 32781946.
- 312 9. Croda J, Oliveira WKd, Frutuoso RL, Mandetta LH, Baia-da-Silva DC, Brito-Sousa JD,
- 313 et al. COVID-19 in Brazil: advantages of a socialized unified health system and
- 314 preparation to contain cases %J Revista da Sociedade Brasileira de Medicina Tropical.
- 315 2020;53.
- 316 10. Amazonas Health Surveillance Foundation FVS. Amazonas confirms 1st case of Covid-
- 317 19 and authorities guarantee that the assistance network is prepared for assistance 2020
- 318 [29 June 2020]. Available from: http://www.fvs.am.gov.br/en/noticias\_view\_en/3740

- 319 11. Amazonas Health Surveillance Foundation FVS. COVID-19 Monitoring Panel. Manaus,
- 320 Brazil 2020 [11 August 2020]. Available from:
- 321 http://www.fvs.am.gov.br/indicadorSalaSituacao\_view/60/2.
- 322 12. Mellan TA, Hoeltgebaum HH, Mishra S. Estimating COVID-19 cases and reproduction
- 323 number in Brazil. Imperial College London, 2020.
- 324 13. de Souza WM, Buss LF, Candido DDS, Carrera JP, Li S, Zarebski AE, et al.
- 325 Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. Nat
- 326 Hum Behav. 2020;4(8):856-65. Epub 2020/08/02. doi: 10.1038/s41562-020-0928-4.
- 327 PubMed PMID: 32737472.
- 328 14. Plummer M. JAGS: A Program for Analysis of Bayesian Graphical Models using Gibbs
- 329 Sampling. 3rd International Workshop on Distributed Statistical Computing (DSC 2003);
- 330 Vienna, Austria. 2003;124.
- 331 15. Zhang J, Litvinova M, Liang Y, Wang Y, Wang W, Zhao S, et al. Changes in contact
- 332 patterns shape the dynamics of the COVID-19 outbreak in China. 2020;368(6498):1481-
- 333 6. doi: 10.1126/science.abb8001 %J Science.
- 16. Davies NG, Klepac P, Liu Y, Prem K, Jit M, Pearson CAB, et al. Age-dependent effects 334
- 335 in the transmission and control of COVID-19 epidemics. Nature Medicine. 2020. doi:
- 336 10.1038/s41591-020-0962-9.
- 337 17. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using
- 338 contact surveys and demographic data. PLOS Comput Biol. 2017;13(9):e1005697. doi:
- 339 10.1371/journal.pcbi.1005697.
- 340 18. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation
- 341 Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed
- 342 Cases: Estimation and Application. Annals of Internal Medicine. 2020;172(9):577-82.
- 343 doi: 10.7326/M20-0504.

- 344 19. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
- 345 shedding and transmissibility of COVID-19. Nature Medicine. 2020;26(5):672-5. doi:
- 346 10.1038/s41591-020-0869-5.
- 347 20. Levin AT, Meyerowitz-Katz G, Owusu-Boaitey N, Cochran KB, Walsh SP. Assessing
- 348 the age specificity of infection fatality rates for COVID-19: systematic review, meta-
- 349 analysis, and public policy implications. 2020:2020.07.23.20160895. doi:
- 350 10.1101/2020.07.23.20160895 %J medRxiv.
- 351 21. United Nations Development Programme. Atlas of human development in Brazil
- 352 (http://www.atlasbrasil.org.br/2013/en/perfil\_m/manaus\_am/, accessed 16/09/2020).
- 353 16/09/2020. Report No.
- 354 22. Excess deaths associated with COVID-19. Provisional death counts for coronavirus
- 355 disease (COVID-19). National Center for Health Statistics, Centers for Disease Control
- 356 and Prevention [updated August 26, 20201st September 2020]. Available from:
- 357 https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess\_deaths.htm.
- 358 23. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of
- 359 individual variation on disease emergence. Nature. 2005;438(7066):355-9. doi:
- 360 10.1038/nature04153.
- 24. Endo A, null n, Abbott S, Kucharski A, Funk S. Estimating the overdispersion in 361
- 362 COVID-19 transmission using outbreak sizes outside China [version 3; peer review: 2
- 363 approved]. 2020;5(67). doi: 10.12688/wellcomeopenres.15842.3.
- 364 25. Levin A, Meyerowitz-Katz G, Owusu-Boaitey N, Cochran K, Walsh S. Assessing the
- 365 age specificity of infection fatality rates for COVID-19: systematic review, meta-
- 366 analysis, and public policy implications. 2020.
- 26. Buss L, Prete CA, Jr., Abrahim C, Mendrone A, Salomon T, de Almeida-Neto C, et al. 367
- 368 COVID-19 herd immunity in the Brazilian Amazon. 2020.

- 369 27. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological
- 370 assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-4.
- 371 Epub 2020/06/20. doi: 10.1038/s41591-020-0965-6. PubMed PMID: 32555424.
- 372 28. Hallal P, Hartwig F, Horta B, Victora G, Silveira M, Struchiner C, et al. Remarkable
- 373 variability in SARS-CoV-2 antibodies across Brazilian regions: nationwide serological
- survey in 27 states. 2020. 374
- 375 29. Rodda L, Netland J, Shehata L, Pruner K, Morawski P, Thouvenel C, et al. Functional
- 376 SARS-CoV-2 specific immune memory persists after mild COVID-19. 2020.
- 377 30. Ledford H. COVID-19 reinfection: three questions scientists are asking. Nature.
- 378 2020;585:168-9.
- 379 31. Britton T, Ball F, Trapman P. A mathematical model reveals the influence of population
- 380 heterogeneity on herd immunity to SARS-CoV-2. 2020;369(6505):846-9. doi:
- 381 10.1126/science.abc6810 %J Science.
- 382 32. Wang Y, Teunis P. Strongly Heterogeneous Transmission of COVID-19 in Mainland
- 383 China: Local and Regional Variation. 2020;7(329). doi: 10.3389/fmed.2020.00329.
- 33. Pybus OG, Rambaut A, du Plessis L, Zarebski AE, Kraemer MUG, Raghwani J, et al. 384
- 385 Preliminary analysis of SARS-CoV-2 importation and establishment of UK transmission
- lineages. 2020. 386
- 387 34. Kluge HHP, Wickramasinghe K, Rippin HL, Mendes R, Peters DH, Kontsevaya A, et al.
- 388 Prevention and control of non-communicable diseases in the COVID-19 response.
- 389 Lancet. 2020;395(10238):1678-80. Epub 2020/05/14. doi: 10.1016/S0140-
- 390 6736(20)31067-9. PubMed PMID: 32401713; PubMed Central PMCID:
- 391 PMCPMC7211494.

392 35. Koopmans M, Haagmans B. Assessing the extent of SARS-CoV-2 circulation through 393 serological studies. Nat Med. 2020;26(8):1171-2. Epub 2020/07/29. doi: 10.1038/s41591-020-1018-x. PubMed PMID: 32719488. 394 395 396

**Fig 1. Excess mortality in Manaus during the COVID-19 epidemic.** (a) Total excess mortality by age and gender for the period between March 19 and June 24 of 2020. Excess mortality is the 2020 weekly observed mortality less the expected mortality summed for the period between March 19 and June 24 of 2020 for each subgroup. (b) Excess mortality for the period between March 19 and June 24 of 2020 divided by the estimated 2019 subgroup populations to obtain population proportions.





Fig 2. Weekly mortality in Manaus by reported cause of death during the COVID-19 epidemic. Observed weekly mortality for the period between January 01 and July 22 of 2020

aggregated by major ICD-10 categories of attributed causes of death.

405

406



**Fig 3. Integrated model fits by gender and model.** Results are pooled at the level of three aggregated age classes: (A) 0-30 years; (B) 30-60 years; and (C) 60+ years. For each age class, panels (i) and (ii) show the fit of the model (lines) to the reported number of deaths and hospitalisations per day (points), while panel (iii) shows inferred attack rates. Note that lines showing the model fits overlap in panels (i) and (ii), and attack rates for males and females overlap in panel (iii).





Fig 4. Estimated infection-fatality and infection-hospitalisation ratios. Model-based estimates (mean  $\pm$  95 % credible intervals) of age- and gender-structured (A) infection-fatality ratios (IFRs) and (B) infection-hospitalisation ratios (IHRs). Note that in panel (A), IFRs were fixed at zero for all age classes below 30 years.



423
424
425
426

Supplementary Material to:
427

Inferred resolution through herd immunity of first
428

COVID-19 wave in Manaus, Brazilian Amazon
429

Thomas A. A. Prowse, T. Purcell, Djane C. Baía-da-Silva, V. Sampaio, Wuelton M.
430

Monteiro, James Wood, I. Mueller, Jodie McVernon, Marcus V. G. Lacerda, Joshua V. Ross

#### 431 Table S1. Excess mortality in Manaus, Amazonas, during the COVID-19 epidemic (here

#### defined as the period between March 19 and June 24, 2020). 432

Age	Females			Males			Total	
	Expected mortality	Observed mortality	Excess mortality	Expected mortality	Observed mortality	Excess mortality	Total Excess mortality	Excess mortality (%)
0-5	84.5	65	-19.5	109.6	83	-26.6	-46.1	-23.7
5-10.	13.2	3	-10.2	19.3	10	-9.3	-19.5	-60
10-15.	13.5	6	-7.5	19.3	11	-8.3	-15.8	-48.2
15-20	26.1	14	-12.1	64.3	45	-19.3	-31.4	-34.7
20-25	24.1	22	-2.1	116.4	78	-38.4	-40.5	-28.8
25-30	26.7	30	3.3	92.2	81	-11.2	-7.9	-6.6
30-35	30	35	5	81.2	88	6.8	11.8	10.6
35-40	38.3	53	14.7	79	118	39	53.7	45.8
40-45	44.6	88	43.5	72.4	154	81.7	125.1	107
45-50	53.3	110	56.7	79.8	184	104.2	160.9	120.8
50-55	59.2	114	54.8	99	225	126	180.8	114.3
55-60	73.2	180	106.8	121.2	310	188.8	295.6	152.1
60-65	95.6	215	119.4	139.2	436	296.8	416.2	177.3
65-70	101.6	283	181.4	148.6	510	361.4	542.8	216.9
70-75	110.2	276	165.8	143.6	456	312.4	478.2	188.4
75+	468.4	996	527.6	382.4	1208	825.6	1353.2	159.1
Total	1262.4	2490	1227.6	1767.5	3997	2229.5	3457.2	114.1

435 436

437




Fig S1. Baseline model fits to daily deaths data for all 32 age and gender classes. Shown are the model-inferred expected death rate from all causes (lines)  $\pm$  95% credible intervals (ribbons), and the mortality data used for model fitting (points).




Fig S2. The fit of Model 2 to daily deaths data for all 32 age and gender classes. Shown are the model-inferred expected death rate from all causes (lines)  $\pm$  95% credible intervals (ribbons), and the mortality data used for model fitting (points).

441




Fig S3. Baseline model fits to hospitalisations data for all 32 age and gender classes. Shown are the model-inferred expected hospitalisation rate (lines)  $\pm$  95% credible intervals (ribbons) and the hospitalisations data used for model fitting (points).

444

445




Fig S4. The fit of Model 2 to hospitalisations data for all 32 age and gender classes. Shown are the model-inferred expected hospitalisation rate (lines)  $\pm$  95% credible intervals (ribbons) and the hospitalisations data used for model fitting (points).

449





Fig S5. Estimates from the baseline model (mean  $\pm$  95 % credible intervals) of the shape of the (A) mortality distribution and (B) hospitalisation distribution, as a function of time since infection. Vertical bars indicate empirical frequencies derived from hospitalisation records for Manaus. In (A), the dashed line indicates the mortality distribution used by a previous COVID-19 modelling study for the State of Amazonas, Brazil [12].

452

453

454

455



**Fig S6.** Estimates from the baseline model (mean  $\pm$  95 % credible intervals) of: (A) the impact of personal mobility on the time-varying reproduction number  $(R_t)$ ; and (B) the population-level effective reproduction number  $(R_{eff})$  over time, which here is calculated as the sum of the products of all  $R_{eff_{(i,j,t)}}$  and the normalised case-infectivity vectors at each time t. In the latter,  $R_{eff}$  rises initially as the case distribution converges on the stable distribution, and  $R_{eff} < 1$  indicates the switch to negative epidemic growth due to the development of herd immunity.

459

460

461

462

463